- Butantan-DV is a dengue vaccine made in Brazil.
- Anvisa approved it on 26 November.
- It is for people aged 12 to 59 years.
- The vaccine needs only one dose to work.
- One dose can help reach remote Amazon communities.
- Trials in Brazil had 16,000 volunteers over nearly a decade.
- The vaccine showed 74.7% overall and 91.6% severe efficacy.
- More than 1,000,000 doses are ready for distribution.
- It will join the national programme in early 2026.
Difficult words
- vaccine — medicine that helps the body avoid disease
- approved — to say yes to a new medicine
- dose — small amount of medicine for one timedoses
- remote — far away from towns and cities
- Trials — study to test a medicine or vaccine
- volunteers — person who joins a study by choice
- efficacy — how well a medicine or vaccine works
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Would you take a vaccine that needs one dose?
- Have you visited a remote area?
Related articles
Emory study: 2023–24 COVID vaccine gives lasting antibodies
Emory University measured antibody responses in 24 people after the 2023–24 monovalent vaccine targeting Omicron XBB.1.5. The study found long-lasting antibodies, cross-reactive protection with the ancestral WA1 strain, and a 2.8-fold boost from immune imprinting.
Teen drug use in the US stays near pandemic low
For the fifth year in a row, use of most substances among US teenagers remains close to the low point reached in 2021, according to the University of Michigan's Monitoring the Future survey. Some drugs rose slightly, and researchers say monitoring must continue.
Virtual diet and exercise program helps people with lymphoma
A study tested a virtual diet and exercise program for people getting chemotherapy for lymphoma. The program improved symptoms, attendance was high, and participants had better strength and physical performance during treatment.
